AndroGel Cost in Illinois 2026: Cash Pay, Insurance, and Compounded Options

What Is the Cash Price of AndroGel in Illinois in 2026?

Without insurance or a discount program, AndroGel 1.62% costs approximately $510 per month at Illinois retail pharmacies in 2026. That figure reflects AbbVie's manufacturer list price and holds relatively stable across major chains such as CVS, Walgreens, and Jewel-Osco pharmacies statewide. GoodRx and similar coupon aggregators may bring the out-of-pocket cost down to the $380, $450 range at select locations, though the discount varies by zip code and pharmacy contract.

AndroGel is FDA-approved for testosterone replacement in adult males with primary or hypogonadal hypogonadism, conditions documented in the product's prescribing information on the FDA access data portal [1]. The gel is applied once daily to the upper arms, shoulders, or abdomen; the 1.62% formulation delivers 20.25 mg of testosterone per pump actuation.

Price sensitivity is real here. A 2022 JAMA Internal Medicine analysis found that out-of-pocket spending on testosterone products varied by a factor of more than four across U.S. pharmacy channels [2], underscoring why comparing options matters before filling a first prescription.

GoodRx-style coupons are not insurance. They cannot be combined with a manufacturer copay card or Medicaid in Illinois, so patients should confirm eligibility for each program before choosing one at the pharmacy counter.

How Does Illinois Medicaid Cover AndroGel?

Illinois Medicaid (administered through the Illinois Department of Healthcare and Family Services) covers AndroGel for male hypogonadism but requires a prior authorization (PA) in every managed-care plan operating in the state. PA criteria generally require a documented serum total testosterone below 300 ng/dL on two morning measurements, plus at least one symptom of hypogonadism such as decreased libido, fatigue, or loss of muscle mass [3].

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, one of the most frequently cited documents in PA submissions, states: "We recommend testosterone therapy for men with classic androgen deficiency syndromes to induce and maintain secondary sex characteristics and to improve their quality of life" [3]. Insurers and Medicaid programs use that language directly in their coverage criteria.

Once approved, most Illinois Medicaid MCOs cover a 30-day supply per fill with no additional cost to the patient. Step-therapy requirements differ by plan; some require a trial of a generic testosterone cypionate injection (available for as little as $12, $25 per month) before approving a brand-name topical gel. Patients who cannot use injections due to needle phobia, clotting disorders, or caregiver limitations can document medical necessity to bypass the step.

Reapproval is typically required every 12 months and must include updated lab values confirming therapeutic response [4]. Illinois HFS publishes its pharmacy prior-authorization forms at hfs.illinois.gov, and most telehealth platforms operating in Illinois will submit the PA on the patient's behalf.

Is Compounded Testosterone Gel Legal in Illinois, and What Does It Cost?

Compounded testosterone gel is legal in Illinois when prepared by a state-licensed 503A compounding pharmacy operating under USP <795> and <797> standards [5]. The "503A" designation comes from Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding based on a valid prescription from a licensed prescriber.

The cost difference is substantial. Compounded testosterone gel in Illinois runs approximately $120 per month, compared with $510 per month for brand-name AndroGel. That is a savings of roughly $390 monthly, or $4,680 annually, for a cash-pay patient.

Common compounded concentrations include testosterone 1%, 2%, and 10% in various bases (Versabase, PLO gel, or ethanol/water). The FDA does not approve compounded formulations, meaning the pharmacokinetics, bioavailability, and sterility of each batch depend entirely on the compounding pharmacy's quality-control program [5]. Patients should verify that their Illinois compounding pharmacy holds an active Illinois Department of Financial and Professional Regulation (IDFPR) license and follows current USP standards.

The T-Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials in 788 men aged 65 and older with low testosterone, used standardized testosterone gel and documented significant improvements in sexual function and bone density [6]. Those findings apply to properly bioavailable formulations; poorly compounded gels with inconsistent absorption may not replicate trial outcomes. A prescriber who monitors serum testosterone levels 2 to 4 weeks after starting a compounded product can confirm adequate absorption before the patient commits to a long-term supply.

Which Insurance Plans Cover AndroGel in Illinois, and How Does Prior Authorization Work?

Most commercial insurance plans available through the Illinois marketplace (Blue Cross Blue Shield of Illinois, Aetna, Cigna, Humana, and United Healthcare) place AndroGel on Tier 3 or Tier 4 of their formularies. Tier 3 copays in Illinois typically run $60, $120 per 30-day supply after the deductible is met; Tier 4 specialty copays can reach $150, $250 [7].

The PA process across commercial plans mirrors Illinois Medicaid: two low morning testosterone values, symptom documentation, and sometimes a failed trial of a lower-cost testosterone formulation. Processing time is 3, 5 business days for standard PA and 24 to 72 hours for urgent requests under Illinois law (215 ILCS 5/155.22b), which requires insurers to act on PA requests within specific timeframes.

Blue Cross Blue Shield of Illinois, the state's largest commercial insurer, lists testosterone gels under its "specialty pharmacy" benefit for plans with that designation, meaning the fill must come from a contracted specialty pharmacy rather than a retail location [8]. Patients should confirm channel requirements before paying out of pocket at a retail pharmacy, because a specialty-channel fill may cost significantly less after insurance.

Employer-sponsored self-insured plans (common among Illinois's large manufacturing and logistics employers) set their own formulary tiers independently of state insurance mandates, so coverage terms can differ substantially from ACA marketplace plans.

How Does the AbbVie Savings Card Work for Illinois Patients?

AbbVie offers the myAbbVie Assist program, which provides AndroGel at $0 copay per month for commercially insured patients who meet eligibility criteria. Patients who are uninsured or covered by a federal or state government program (including Illinois Medicaid, Medicare, or TRICARE) are not eligible for the commercial copay card [9].

For eligible commercially insured Illinois patients, the card reduces the out-of-pocket cost to $0 per fill for up to 12 fills per year, subject to a maximum benefit cap that AbbVie sets annually. Enrollment is done online at abbvie.com or through a prescribing physician's office. Most HealthRX-affiliated Illinois prescribers enroll patients in the program at the time of prescribing so that the card is ready at the first pharmacy visit.

The program does not cover compounded testosterone. It applies only to brand-name AndroGel dispensed at a licensed U.S. retail or specialty pharmacy.

Patients who lose commercial insurance during the year (for example, due to a job change) should notify AbbVie immediately, because continued use of the copay card after transitioning to a government plan constitutes a federal compliance violation under anti-kickback statutes.

What Is the Cheapest Way to Get Testosterone Gel in Illinois?

The lowest-cost path depends on insurance status. The table below summarizes monthly cost estimates for Illinois patients in 2026.

| Option | Estimated Monthly Cost (Illinois) | |---|---| | AndroGel, no insurance, no coupon | ~$510 | | AndroGel with GoodRx coupon | ~$380, $450 | | AndroGel with AbbVie copay card (commercially insured) | $0 | | AndroGel via commercial insurance (Tier 3) | $60, $120 after deductible | | Compounded testosterone gel (503A pharmacy) | ~$120 | | Generic testosterone cypionate injection | $12, $25 |

Generic testosterone cypionate injection is the least expensive testosterone therapy available in Illinois by a wide margin. It requires intramuscular or subcutaneous self-injection, typically weekly or every two weeks, and it is not a topical gel. Patients who specifically need a gel formulation (due to skin tolerance, occupational exposure concerns, or prescriber preference) will find compounded gel at approximately $120/month to be the most cost-effective topical option.

A cost-minimization framework for Illinois patients: start with insurance verification and formulary lookup, then apply the AbbVie card if commercially insured, then consider compounded gel if uninsured or if the commercial plan denies coverage after appeal. Injectable testosterone is appropriate when cost is the overriding concern and the patient has no contraindication to injection.

What Do the Clinical Trials Say About Testosterone Gel Efficacy?

Efficacy data for testosterone gel come primarily from the T-Trials and several industry-sponsored registration studies submitted to the FDA. The T-Trials enrolled 788 men aged 65 years or older with a serum testosterone below 275 ng/dL and at least one symptom of hypogonadism [6]. Across the sexual-function sub-trial, testosterone gel increased sexual activity scores significantly versus placebo over 12 months (P<0.001), though the absolute improvement was modest in absolute terms.

The AndroGel 1.62% registration trial (N=234) showed that 75.7% of men reached normal testosterone range (300, 1 to 000 ng/dL) at 12 weeks on doses between 20.25 mg and 81 mg daily [1]. Serum levels stabilize within 24 to 48 hours of dose adjustment, which makes titration straightforward compared with injectable formulations whose peaks and troughs span days.

A 2020 meta-analysis in the Journal of Clinical Endocrinology and Metabolism examined 35 randomized controlled trials of testosterone replacement and found significant improvements in lean mass, fat mass, and sexual function, with no statistically significant increase in cardiovascular events at standard doses over trial durations of up to 36 months [10]. The Endocrine Society guideline cautions that men with a hematocrit above 54%, untreated severe obstructive sleep apnea, or active prostate cancer should not receive testosterone therapy [3].

Monitoring recommendations from the American Urological Association include serum testosterone at 3 to 6 months after initiation, then annually; hematocrit at the same intervals; and a digital rectal exam plus PSA at 3 to 12 months after starting and annually thereafter in men over 40 [11].

Can I Get an AndroGel Prescription via Telehealth in Illinois?

Yes. Illinois permits telehealth prescribing of controlled substances, including Schedule III testosterone products, under rules aligned with the Ryan Haight Online Pharmacy Consumer Protection Act and the DEA's telemedicine flexibilities that have been extended through 2025 and into the transition period for 2026 [12]. A prescriber licensed in Illinois can evaluate a patient via synchronous audio-video visit and issue a controlled-substance prescription without an in-person visit, provided the platform meets DEA and Illinois Department of Professional Regulation requirements.

The practical requirement is a laboratory result showing low testosterone before or shortly after the initial visit. Most Illinois-licensed telehealth platforms (including HealthRX) direct patients to a local Quest Diagnostics or LabCorp draw site for a morning total testosterone and, typically, LH, FSH, hematocrit, and PSA before the first prescribing encounter.

Prescriptions for AndroGel issued via telehealth in Illinois are valid at any licensed Illinois retail pharmacy or may be routed to a compounding pharmacy by the prescribing provider. The prescription must be transmitted electronically under Illinois's electronic prescribing of controlled substances (EPCS) mandate, which has been in effect since January 2022 [13].

Monitoring and Safety Points Illinois Patients Should Know

Testosterone gel carries a black-box FDA warning about secondary exposure: children and women who contact the application site before the gel dries may absorb testosterone transdermally, leading to premature puberty or virilization [1]. The FDA documented 20 pediatric cases of secondary exposure between 2000 and 2009 before adding the black-box warning. Patients should wash hands after application and cover the site with clothing.

The Testosterone and Cardiovascular Events in Men with Testosterone Deficiency (TRAVERSE) trial, published in the New England Journal of Medicine in 2023, enrolled 5,246 men with hypogonadism and pre-existing or high-risk cardiovascular disease. Testosterone replacement was non-inferior to placebo for major adverse cardiovascular events (MACE) over a mean follow-up of 33 months, though the trial showed a higher incidence of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism in the testosterone group [14]. Illinois prescribers should document cardiovascular risk factors at baseline and reassess annually.

Hematocrit elevation above 54% requires dose reduction or temporary discontinuation regardless of symptoms, per FDA prescribing guidance [1]. Routine CBC monitoring at 3 and 12 months catches this reliably.